Full text
Earnings transcript
Read the complete earnings call transcript.
AVXL
Anavex Life Sciences Corp.
$1.48
-0.03
(-1.99%)
| Exchange: | NASDAQ |
| Market Cap: | 137.154M |
| Shares Outstanding: | 58.195M |
Delayed data
About The Company
| Sector: | HealthcareView sector performance | |||||
| Industry: | BiotechnologyView industry performance | |||||
| CEO: | Terrie Kellmeyer | |||||
| Full Time Employees: | 34 | |||||
| Address: |
| |||||
| Website: | https://www.anavex.com |
Operating as a clinical-stage biopharmaceutical entity, Anavex Life Sciences Corp. specializes in developing therapeutic drug candidates for various central nervous system (CNS) conditions. Its leading compound, ANAVEX 2-73, is currently in advanced development, undergoing Phase III clinical evaluation for both Alzheimer’s disease and pediatric Rett syndrome. This same drug is also in Phase II trials for Parkinson’s disease and is being explored in preclinical studies for a wider range of disorders, including epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. Another significant drug candidate, ANAVEX 3-71, has progressed to Phase I clinical trials for frontotemporal dementia and other forms of dementia, with additional preclinical investigation underway for neurodegenerative illnesses like Alzheimer’s and Parkinson’s. The company’s earlier-stage portfolio includes ANAVEX 1-41, a sigma-1 receptor agonist targeting depression, stroke, Parkinson’s, and Alzheimer’s diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand with potential applications in neuropathic and visceral pain; and ANAVEX 1037, aimed at treating prostate and pancreatic cancers. Anavex Life Sciences Corp. was founded in 2004 and maintains its headquarters in New York, New York.
Click to read more…
Revenue Segmentation
AVXL full analysis
Hey everyone, welcome back to the channel. Today we're diving deep into Anavex Life Sciences, ticker AVXL, a clinical-stage biotech that's been making waves in the CNS space. Let's break down the full picture from the financials to the pipeline and what it could mean for investors. Anavex is a small-cap player focused on developing therapies for neurodegenerative and neurodevelopmental disorders. With a market cap sitting around 253 million and shares trading near around 3 dollars, this is a high-risk,…
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
AI summary
Key takeaways
Short, structured highlights from the call so you can focus on what matters.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 |
| EBITDA | -46,541 | -43,002 | -46,377 |
| Operating Income | -55,763 | -52,877 | -51,408 |
| Net Income | -47,505 | -43,002 | -46,377 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total Assets | 154,386 | 135,567 | 103,815 |
| Total Liabilities | 12,534 | 15,304 | 8,946 |
| Total Stockholders Equity | 141,852 | 120,263 | 94,869 |
| Total Debt | 0 | 0 | 0 |
| Cash and Cash Equivalents | 151,024 | 132,187 | 102,577 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating Cash Flow | -27,785 | -30,812 | -39,044 |
| Capital Expenditure | 0 | 0 | 0 |
| Free Cash Flow | -27,785 | -30,812 | -39,044 |
| Net Income | -47,505 | -43,002 | -46,377 |
| Net Change in Cash | 1,866 | -18,837 | -29,610 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2030 | Research Access | Research Access | Research Access | Research Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 885,110 | Research Access | Research Access | Research Access | Research Access |
| Estimated Revenue (High) | 885,110 | Research Access | Research Access | Research Access | Research Access |
| Estimated Revenue (Avg) | 885,110 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (Low) | 564,959.333 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (High) | 564,959.333 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (Avg) | 564,959.333 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (Low) | 446,063.813 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (High) | 446,063.813 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (Avg) | 446,063.813 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (Low) | 0 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (High) | 0 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (Avg) | 0 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (Avg) | 5.230 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (High) | 5.230 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (Low) | 5.230 | Research Access | Research Access | Research Access | Research Access |
| Number of Analysts (Estimated Revenue) | 1 | Research Access | Research Access | Research Access | Research Access |
| Number of Analysts (Estimated EPS) | 1 | Research Access | Research Access | Research Access | Research Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
Strengths (preview)
- Comprehensive financial metrics available including currentRatioTTM, quickRatioTTM, and debtToEquityRatioTTM for liquidity and leverage assessment.
- Detailed balance sheet and cash flow data covering cashAndCashEquivalents, totalAssets, freeCashFlow, and netCashProvidedByOperatingActivities to evaluate capital position.
- Access to performance metrics across multiple timeframes (perf1w to perf5y) alongside industry and sector benchmarks for relative positioning.
Log in with Research Access for Weaknesses, Opportunities, Threats, and the complete SWOT.
At what price to buy it? -
Intrinsic Value Calculator
Based on current fundamentals and analyst forecasts, MarketSnap estimates AVXL intrinsic value between $2.48 – $5.46 per share. This depends on revenue growth, margins, and discount rate.
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
Common questions about AVXL valuation
Is Anavex Life Sciences Corp. (AVXL) overvalued or undervalued right now?
MarketSnap estimates intrinsic value for Anavex Life Sciences Corp. (AVXL) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is AVXL a buy, hold, or sell for long-term investors?
MarketSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether AVXL trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is AVXL’s P/E ratio?
You can see AVXL’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for AVXL?
MarketSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MarketSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is AVXL a good long-term investment?
Whether AVXL fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MarketSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
AVXL
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
Daily snapshot
-1.99
Trading Metrics:
| Open: | 1.53 | Previous Close: | 1.51 | |
| Day Low: | 1.48 | Day High: | 1.53 | |
| Year Low: | 1.44 | Year High: | 9.5 | |
| Price Avg 50: | 2.68 | Price Avg 200: | 3.28 | |
| Volume: | 1.195M | Average Volume: | 1.101M |
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's free
